ANZCTR - Registration

Registration number

NCT03850535

Ethics application status

Date submitted

20/02/2019

Date registered

21/02/2019

Date last updated

21/06/2022

Titles & IDs

Public title

A Study Evaluating the Safety and Efficacy of Idasanutlin in Combination With Cytarabine and Daunorubicin in Patients Newly Diagnosed With Acute Myeloid Leukemia (AML) and the Safety and Efficacy of Idasanutlin in the Maintenance of First AML Complete Remission

Scientific title

A Phase Ib/II Study Evaluating the Safety and Efficacy of Idasanutlin in Combination With Cytarabine and Daunorubicin in Patients Newly Diagnosed With Acute Myeloid Leukemia (AML) and the Safety and Efficacy of Idasanutlin in the Maintenance of First AML Complete Remission

Secondary ID [1]

2018-002964-25

Secondary ID [2]

GO40800

Universal Trial Number (UTN)

Trial acronym

Linked study record

Health condition

Health condition(s) or problem(s) studied:

Acute Myeloid Leukemia

Condition category

Condition code

Cancer

Leukaemia - Acute leukaemia

Cancer

Leukaemia - Chronic leukaemia

Cancer

Children's - Leukaemia & Lymphoma

Intervention/exposure

Study type

Interventional

Description of intervention(s) / exposure

Treatment: Drugs - Idasanutlin
Treatment: Drugs - Cytarabine
Treatment: Drugs - Daunorubicin
Treatment: Surgery - Allogeneic Hematopoietic Stem Cell Transplant (Allo-HSCT)

Experimental: Dose-Escalation Phase - Participants with newly diagnosed, previously untreated, favorable or intermediate risk AML (according to European LeukemiaNet [ELN] 2017 criteria) will undergo the treatment sequence of induction, consolidation, and maintenance. For induction, participants will be treated with idasanutlin plus cytarabine and daunorubicin. At the investigator's discretion for consolidation, either participants will be treated with idasanutlin and cytarabine or they will undergo Allo-HSCT. For maintenance, participants will be treated with single-agent idasanutlin.

Experimental: Post-Consolidation Phase - Participants who are idasanutlin treatment-naive, had received induction and chemotherapy consolidation for AML outside of the study, and were in minimal residual disease (MRD)-positive remission after induction will be enrolled in this cohort to receive maintenance treatment with single-agent idasanutlin.

Experimental: Expansion Phase: Favorable/Intermediate-Risk AML - Participants with newly diagnosed, previously untreated, favorable or intermediate risk AML (according to ELN 2017 criteria) will undergo the treatment sequence of induction, consolidation, and maintenance. For induction, participants will be treated with idasanutlin (at the recommended Phase 2 dose) plus cytarabine and daunorubicin. At the investigator's discretion for consolidation, either participants will be treated with idasanutlin and cytarabine or they will undergo Allo-HSCT. For maintenance, participants will be treated with single-agent idasanutlin.

Experimental: Expansion Phase: High-Risk AML - Participants with newly diagnosed, previously untreated, high-risk AML (defined as adverse risk according to ELN 2017 criteria, and secondary AML) will undergo the treatment sequence of induction, consolidation, and maintenance. For induction, participants will be treated with idasanutlin (at the recommended Phase 2 dose) plus cytarabine and daunorubicin. At the investigator's discretion for consolidation, either participants will be treated with idasanutlin and cytarabine or they will undergo Allo-HSCT. For maintenance, participants will be treated with single-agent idasanutlin.

Treatment: Drugs: Idasanutlin
Participants will self-administer idasanutlin tablets by mouth (PO) once daily (QD) for 5 days of each 28-day treatment cycle for up to 2 cycles of induction, up to 4 cycles of consolidation, and 12 cycles of maintenance, according to the study's protocol.

Treatment: Drugs: Cytarabine
Cytarabine will be administered for 7 days of each 28-day cycle for up to 2 cycles of induction treatment at a dose of 200 milligrams per meter squared (mg/m^2) of body surface area, once daily (QD) by intravenous (IV) infusion. At the investigator's discretion, cytarabine will also be administered as part of chemotherapy consolidation at a dose of 1.5 g/m^2 QD as IV infusion for 5 days of each 28-day cycle and for up to 4 cycles of treatment.

Treatment: Drugs: Daunorubicin
Daunorubicin will be administered for 3 days of each 28-day cycle for up to 2 cycles of induction treatment at a dose of 60 mg/m^2 QD as IV infusion.

Treatment: Surgery: Allogeneic Hematopoietic Stem Cell Transplant (Allo-HSCT)
After induction treatment, participants who achieve remission will either receive chemotherapy consolidation treatment or undergo Allo-HSCT (as per local guidelines) at the investigator's discretion.

Intervention code [1]

Treatment: Drugs

Intervention code [2]

Treatment: Surgery

Comparator / control treatment

Control group

Outcomes

Primary outcome [1]

Dose Escalation Phase: Number of Participants With Dose-Limiting Toxicities (DLTs) During the First Cycle of Induction Treatment

Timepoint [1]

Cycle 1 of induction treatment (1 cycle is 28 days)

Primary outcome [2]

Number of Participants With at Least One Adverse Event

Timepoint [2]

From Baseline until 28 days after the final dose of study drug (up to 2 years)

Primary outcome [3]

Number of Participants With Grade =3 Adverse Events, Severity Determined According to National Cancer Institute Common Terminology Criteria for Adverse Events, Version 5.0 (NCI CTCAE v5.0)

Timepoint [3]

From Baseline until 28 days after the final dose of study drug (up to 2 years)

Primary outcome [4]

Number of Participants Reporting Presence or Absence of Nausea Over Time, as Assessed Through Use of the National Cancer Institute (NCI) Patient-Reported Outcomes Common Terminology Criteria for Adverse Events (PRO-CTCAE)

Timepoint [4]

Day 1 of each treatment cycle (1 cycle is 28 days) and at study drug discontinuation (up to 2 years)

Primary outcome [5]

Change From Baseline Over Time in Reported Frequency of Nausea, as Assessed Through Use of the NCI PRO-CTCAE

Timepoint [5]

Baseline, Day 1 of each treatment cycle (1 cycle is 28 days), and at study drug discontinuation (up to 2 years)

Primary outcome [6]

Change From Baseline Over Time in Reported Severity of Nausea, as Assessed Through Use of the NCI PRO-CTCAE

Timepoint [6]

Baseline, Day 1 of each treatment cycle (1 cycle is 28 days), and at study drug discontinuation (up to 2 years)

Primary outcome [7]

Change From Baseline Over Time in Reported Degree of Interference With Daily Function Caused by Nausea, as Assessed Through Use of the NCI PRO-CTCAE

Timepoint [7]

Baseline, Day 1 of each treatment cycle (1 cycle is 28 days), and at study drug discontinuation (up to 2 years)

Primary outcome [8]

Change From Baseline Over Time in Overall Score for Nausea, as Assessed Through Use of the NCI PRO-CTCAE

Timepoint [8]

Baseline, Day 1 of each treatment cycle (1 cycle is 28 days), and at study drug discontinuation (up to 2 years)

Primary outcome [9]

Number of Participants Reporting Presence or Absence of Vomiting Over Time, as Assessed Through Use of the NCI PRO-CTCAE

Timepoint [9]

Day 1 of each treatment cycle (1 cycle is 28 days) and at study drug discontinuation (up to 2 years)

Primary outcome [10]

Change From Baseline Over Time in Reported Frequency of Vomiting, as Assessed Through Use of the NCI PRO-CTCAE

Timepoint [10]

Baseline, Day 1 of each treatment cycle (1 cycle is 28 days), and at study drug discontinuation (up to 2 years)

Primary outcome [11]

Change From Baseline Over Time in Reported Severity of Vomiting, as Assessed Through Use of the NCI PRO-CTCAE

Timepoint [11]

Baseline, Day 1 of each treatment cycle (1 cycle is 28 days), and at study drug discontinuation (up to 2 years)

Primary outcome [12]

Change From Baseline Over Time in Reported Degree of Interference With Daily Function Caused by Vomiting, as Assessed Through Use of the NCI PRO-CTCAE

Timepoint [12]

Baseline, Day 1 of each treatment cycle (1 cycle is 28 days), and at study drug discontinuation (up to 2 years)

Primary outcome [13]

Change From Baseline Over Time in Overall Score for Vomiting, as Assessed Through Use of the NCI PRO-CTCAE

Timepoint [13]

Baseline, Day 1 of each treatment cycle (1 cycle is 28 days), and at study drug discontinuation (up to 2 years)

Primary outcome [14]

Number of Participants Reporting Presence or Absence of Diarrhea Over Time, as Assessed Through Use of the NCI PRO-CTCAE Over Time

Timepoint [14]

Day 1 of each treatment cycle (1 cycle is 28 days) and at study drug discontinuation (up to 2 years)

Primary outcome [15]

Change From Baseline in Reported Frequency of Diarrhea Over Time, as Assessed Through Use of the NCI PRO-CTCAE

Timepoint [15]

Baseline, Day 1 of each treatment cycle (1 cycle is 28 days), and at study drug discontinuation (up to 2 years)

Primary outcome [16]

Change From Baseline in Reported Severity of Diarrhea Over Time, as Assessed Through Use of the NCI PRO-CTCAE

Timepoint [16]

Baseline, Day 1 of each treatment cycle (1 cycle is 28 days), and at study drug discontinuation (up to 2 years)

Primary outcome [17]

Change From Baseline in Reported Degree of Interference With Daily Function Caused by Diarrhea Over Time, as Assessed Through Use of the NCI PRO-CTCAE

Timepoint [17]

Baseline, Day 1 of each treatment cycle (1 cycle is 28 days), and at study drug discontinuation (up to 2 years)

Primary outcome [18]

Change From Baseline in Overall Score for Diarrhea Over Time, as Assessed Through Use of the NCI PRO-CTCAE

Timepoint [18]

Baseline, Day 1 of each treatment cycle (1 cycle is 28 days), and at study drug discontinuation (up to 2 years)

Primary outcome [19]

Number of Participants, Per ELN Categories, With a Complete Remission (CR) at the End of Induction Treatment, Among Those Treated at the Recommended Phase 2 Dose

Timepoint [19]

At the end of induction treatment (up to 2 cycles; 1 cycle is 28 days)

Secondary outcome [1]

Dose Escalation and Expansion Phases: Percentage of Participants With a CR, Complete Remission With Incomplete Blood Count Recovery (CRi), or Complete Remission With Incomplete Platelet Count Recovery (CRp) at the End of Induction Treatment

Timepoint [1]

At the end of induction treatment (up to 2 cycles; 1 cycle is 28 days)

Secondary outcome [2]

Dose Escalation and Expansion Phases: Percentage of Participants With a CR or Complete Remission With Partial Hematologic Recovery (CRh) at the End of Induction Treatment

Timepoint [2]

At the end of induction treatment (up to 2 cycles; 1 cycle is 28 days)

Secondary outcome [3]

Dose-Escalation and Expansion Phases: Percentage of Participants With a Negative Minimal Residual Disease (MRD) Status at the End of Induction Treatment

Timepoint [3]

At the end of induction treatment (up to 2 cycles; 1 cycle is 28 days)

Secondary outcome [4]

Post-Consolidation Phase: Percentage of Participants Converting From MRD-Positive to MRD-Negative Status at Any Time During Treatment

Timepoint [4]

At the end of maintenance treatment (12 cycles, 1 cycle is 28 days)

Secondary outcome [5]

Kaplan-Meier Estimate of the Percentage of Participants in Event-Free Survival

Timepoint [5]

Up to 5 years

Secondary outcome [6]

Kaplan-Meier Estimate of the Percentage of Participants in Overall Survival

Timepoint [6]

Up to 5 years

Secondary outcome [7]

Kaplan-Meier Estimate of the Percentage of Participants in Relapse-Free Survival in Those Who Achieve Remission (CR, CRi, CRp, or CRh)

Timepoint [7]

Up to 5 years

Secondary outcome [8]

Change From Baseline Over Time in the Participant-Reported Functional Assessment of Chronic Illness Therapy (FACIT)-Fatigue Questionnaire Total Score

Timepoint [8]

Baseline, Day 1 of each cycle of induction and consolidation (1 cycle is 28 days), every 3 months starting at Cycle 1 of maintenance, and at study drug discontinuation (up to 2 years)

Secondary outcome [9]

Change From Baseline Over Time in Physical Function Scale Score of the Participant-Reported European Organisation for Research and Treatment of Cancer Quality-of-Life Questionnaire, Core 30 (EORTC QLQ-C30)

Timepoint [9]

Baseline, Day 1 of first induction cycle only, Day 1 of each subsequent treatment cycle (1 cycle is 28 days), and at study drug discontinuation (up to 2 years)

Secondary outcome [10]

Change From Baseline Over Time in Role Function Scale Score of the Participant-Reported EORTC QLQ-C30

Timepoint [10]

Baseline, Day 1 of first induction cycle only, Day 1 of each subsequent treatment cycle (1 cycle is 28 days), and at study drug discontinuation (up to 2 years)

Secondary outcome [11]

Change From Baseline Over Time in Global Health Status/Quality of Life Scale Score of the Participant-Reported EORTC QLQ-C30

Timepoint [11]

Baseline, Day 1 of first induction cycle only, Day 1 of each subsequent treatment cycle (1 cycle is 28 days), and at study drug discontinuation (up to 2 years)

Secondary outcome [12]

Change From Baseline Over Time in Headache Symptom Score of the Participant-Reported European Organisation for Research and Treatment of Cancer (EORTC) Item Library Questionnaire

Timepoint [12]

Baseline, Day 1 of each cycle of induction and consolidation (1 cycle is 28 days), every 3 months starting at Cycle 1 of maintenance, and at study drug discontinuation (up to 2 years)

Secondary outcome [13]

Change From Baseline Over Time in Dizziness Symptom Score of the Participant-Reported EORTC Item Library Questionnaire

Timepoint [13]

Baseline, Day 1 of each cycle of induction and consolidation (1 cycle is 28 days), every 3 months starting at Cycle 1 of maintenance, and at study drug discontinuation (up to 2 years)

Secondary outcome [14]

Change From Baseline Over Time in Bruising Symptom Score of the Participant-Reported EORTC Item Library Questionnaire

Timepoint [14]

Baseline, Day 1 of each cycle of induction and consolidation (1 cycle is 28 days), every 3 months starting at Cycle 1 of maintenance, and at study drug discontinuation (up to 2 years)

Secondary outcome [15]

Change From Baseline Over Time in the European Quality of Life 5-Dimension, 5-Level Questionnaire (EQ-5D-5L) Index Utility Score

Timepoint [15]

Baseline, Day 1 of first induction cycle only, Day 1 of all cycles of consolidation (1 cycle is 28 days), every 3 months starting at Cycle 1 of maintenance, and at study drug discontinuation (up to 2 years)

Secondary outcome [16]

Change From Baseline Over Time in the EQ-5D-5L Visual Analogue Scale (VAS) Score

Timepoint [16]

Baseline, Day 1 of first induction cycle only, Day 1 of all cycles of consolidation (1 cycle is 28 days), every 3 months starting at Cycle 1 of maintenance, and at study drug discontinuation (up to 2 years)

Secondary outcome [17]

Area Under the Plasma Concentration-Time Curve (AUC) of Idasanutlin

Timepoint [17]

Pre-dose and at predefined intervals post-dose on Days 1, 3, and 5 of induction Cycle 1; Days 1 and 5 of consolidation Cycle 1; and Days 1 and 5 of maintenance Cycle 1 (1 cycle is 28 days)

Secondary outcome [18]

AUC of Cytarabine

Timepoint [18]

Pre-dose and at predefined intervals post-dose on Days 1, 3, and 5 of induction Cycle 1; and Days 1 and 5 of consolidation Cycle 1 (1 cycle is 28 days)

Secondary outcome [19]

AUC of Daunorubicin

Timepoint [19]

Pre-dose and at predefined intervals post-dose on Days 1, 3, and 5 of induction Cycle 1 (1 cycle is 28 days)

Secondary outcome [20]

Maximum Observed Plasma Concentration (Cmax) of Idasanutlin

Timepoint [20]

Pre-dose and at predefined intervals post-dose on Days 1, 3, and 5 of induction Cycle 1; Days 1 and 5 of consolidation Cycle 1; and Days 1 and 5 of maintenance Cycle 1 (1 cycle is 28 days)

Secondary outcome [21]

Cmax of Cytarabine

Timepoint [21]

Pre-dose and at predefined intervals post-dose on Days 1, 3, and 5 of induction Cycle 1; and Days 1 and 5 of consolidation Cycle 1 (1 cycle is 28 days)

Secondary outcome [22]

Cmax of Daunorubicin

Timepoint [22]

Pre-dose and at predefined intervals post-dose on Days 1, 3, and 5 of induction Cycle 1 (1 cycle is 28 days)

Secondary outcome [23]

Total Clearance (CL) of Idasanutlin

Timepoint [23]

Pre-dose and at predefined intervals post-dose on Days 1, 3, and 5 of induction Cycle 1; Days 1 and 5 of consolidation Cycle 1; and Days 1 and 5 of maintenance Cycle 1 (1 cycle is 28 days)

Secondary outcome [24]

CL of Cytarabine

Timepoint [24]

Pre-dose and at predefined intervals post-dose on Days 1, 3, and 5 of induction Cycle 1; and Days 1 and 5 of consolidation Cycle 1 (1 cycle is 28 days)

Secondary outcome [25]

CL of Daunorubicin

Timepoint [25]

Pre-dose and at predefined intervals post-dose on Days 1, 3, and 5 of induction Cycle 1 (1 cycle is 28 days)

Secondary outcome [26]

Volume of Distribution at Steady State (Vss) of Idasanutlin

Timepoint [26]

Pre-dose and at predefined intervals post-dose on Days 1, 3, and 5 of induction Cycle 1; Days 1 and 5 of consolidation Cycle 1; and Days 1 and 5 of maintenance Cycle 1 (1 cycle is 28 days)

Secondary outcome [27]

Vss of Cytarabine

Timepoint [27]

Pre-dose and at predefined intervals post-dose on Days 1, 3, and 5 of induction Cycle 1; and Days 1 and 5 of consolidation Cycle 1 (1 cycle is 28 days)

Secondary outcome [28]

Vss of Daunorubicin

Timepoint [28]

Pre-dose and at predefined intervals post-dose on Days 1, 3, and 5 of induction Cycle 1 (1 cycle is 28 days)

Secondary outcome [29]

Terminal Half-Life (t1/2) of Idasanutlin

Timepoint [29]

Pre-dose and at predefined intervals post-dose on Days 1, 3, and 5 of induction Cycle 1; Days 1 and 5 of consolidation Cycle 1; and Days 1 and 5 of maintenance Cycle 1 (1 cycle is 28 days)

Secondary outcome [30]

t1/2 of Cytarabine

Timepoint [30]

Pre-dose and at predefined intervals post-dose on Days 1, 3, and 5 of induction Cycle 1; and Days 1 and 5 of consolidation Cycle 1 (1 cycle is 28 days)

Secondary outcome [31]

t1/2 of Daunorubicin

Timepoint [31]

Pre-dose and at predefined intervals post-dose on Days 1, 3, and 5 of induction Cycle 1 (1 cycle is 28 days)

Eligibility

Key inclusion criteria

Inclusion Criteria for All Study Phases:

- Eastern Cooperative Oncology Group (ECOG) performance status =2

- Adequate hepatic and renal function

- For women of childbearing potential: agreement to remain abstinent (refrain from
heterosexual intercourse) or use contraceptive measures, and agreement to refrain from
donating eggs with a failure rate of <1% per year during the treatment period and for
at least 6 months after the final dose of idasanutlin, cytarabine, or daunorubicin.
Women must refrain from donating eggs during this same period.

- For men: agreement to remain abstinent (refrain from heterosexual intercourse) or use
contraceptive, measures, and agreement to refrain from donating sperm that together
result in a failure rate of <1% per year during the treatment period and for 6 months
after the final dose of idasanutlin, cytarabine, or daunorubicin. Men must refrain
from donating sperm during this same period.

Inclusion Criteria for Patients in the Dose-Escalation and Expansion Phases:

- Documented/confirmed newly diagnosed acute myeloid leukemia (AML) not previously treated
according to World Health Organization (WHO)

Inclusion Criteria for Patients in the Post-Consolidation Phase:

- Documented/confirmed AML according to WHO in remission after induction, within 21 days of
end of last chemotherapy consolidation cycle, and were minimum residual disease (MRD)
positive at the end of induction as per local laboratory assessment

Minimum age

18 Years

Maximum age

No limit

Sex

Both males and females

Can healthy volunteers participate?

No

Key exclusion criteria

Exclusion Criteria for All Study Phases:

- Clinical evidence of central nervous system (CNS) leukemia

- Any Grade =2 non-hematologic toxicities prior to starting therapy

- Current treatment with any other investigational or commercial agents or therapies
administered with the intention to treat their malignancy with the exception of
hydroxyurea (HU) or 6-mercaptopurine (6-MP)

- Treatment-related AML

- Acute promyelocytic leukemia

- History of other malignancy that could affect compliance with the protocol or
interpretation of results

- Any severe and/or uncontrolled medical conditions or other conditions that could
affect their participation in the study, impair the ability of the investigator to
evaluate the patient, or impair the patient's ability to complete the study

- Echocardiogram (ECHO) or multiple-gated acquisition (MUGA) scan showing ejection
fraction =40%

- Non-malignant medical illnesses that are uncontrolled or whose control may be
jeopardized by this study treatment, such as hereditary coagulation disorders,
insulin-dependent diabetes mellitus not optimally controlled with medical management
(e.g., presence of ketoacidosis), or active GI conditions affecting absorption

- Infection considered by the investigator to be clinically uncontrolled or of
unacceptable risk to the patient upon the induction of neutropenia, that is, patients
who are or should be on antimicrobial agents for the treatment of active infection

- Febrile patients within 72 hours of study treatment initiation

- Patients with a history of active or chronic infectious hepatitis unless serology
demonstrates clearance of infection

- Patients who are unable to interrupt treatment with moderate to strong CYP2C8 inducers
and inhibitors

- Patients who are unable to temporarily interrupt treatment with oral or parenteral
anticoagulants/anti-platelet agents during treatment phase

- Patients who have a history of clinically significant liver cirrhosis

- Patients with extramedullary AML with no evidence of systemic involvement

- Pregnant or breastfeeding patients

- Known history of HIV-positive status

- Patients who might refuse to receive blood products and/or have a hypersensitivity to
blood products

- Prior treatment with an MDM2 antagonist

- Patients with clinically relevant QTc prolongation, a family history of long QT
syndrome

Exclusion Criteria for Patients in the Phase Ib Dose-Escalation Phase:

- Adverse risk patients as per European LeukemiaNet (ELN) 2017 criteria

Exclusion Criteria for Patients in Phase Ib Post-Consolidation Phase:

- Any ongoing Grade =2 hematologic adverse events prior to starting therapy

- Previous hematopoietic stem cell transplant (HSCT)

Exclusion Criteria for Patients in the Dose-Escalation Phase and Patients in the
Favorable/Intermediate-Risk Cohort of the Expansion Phase:

- Secondary AML, defined as AML evolving from antecedent hematologic disorder (AHD)

Study design

Statistical methods / analysis

Recruitment

Recruitment status

Terminated

Date of first participant enrolment

Anticipated

Actual

25/03/2019

Date of last participant enrolment

Anticipated

Actual

Date of last data collection

Anticipated

Actual

10/09/2020

Sample size

Target

Accrual to date

Final

24

Recruitment in Australia

Recruitment state(s)

VIC,WA

Recruitment hospital [1]

The Alfred Hospital - Prahan

Recruitment hospital [2]

Royal Perth Hospital - Perth

Recruitment postcode(s) [1]

3181 - Prahan

Recruitment postcode(s) [2]

6000 - Perth

Recruitment outside Australia

Country [1]

United States of America

State/province [1]

California

Country [2]

United States of America

State/province [2]

Colorado

Country [3]

United States of America

State/province [3]

Illinois

Country [4]

United States of America

State/province [4]

Iowa

Country [5]

United States of America

State/province [5]

Kansas

Country [6]

United States of America

State/province [6]

Massachusetts

Country [7]

United States of America

State/province [7]

New York

Country [8]

United States of America

State/province [8]

North Carolina

Country [9]

United States of America

State/province [9]

Ohio

Country [10]

United States of America

State/province [10]

Pennsylvania

Country [11]

United States of America

State/province [11]

Texas

Country [12]

France

State/province [12]

Lyon

Country [13]

France

State/province [13]

Marseille

Country [14]

France

State/province [14]

Nantes

Country [15]

France

State/province [15]

Paris

Country [16]

France

State/province [16]

Toulouse

Country [17]

Italy

State/province [17]

Emilia-Romagna

Country [18]

Italy

State/province [18]

Lombardia

Country [19]

Spain

State/province [19]

Barcelona

Country [20]

Spain

State/province [20]

Madrid

Country [21]

Spain

State/province [21]

Sevilla

Country [22]

Spain

State/province [22]

Valencia

Funding & Sponsors

Primary sponsor type

Commercial sector/Industry

Name

Hoffmann-La Roche

Country

Ethics approval

Ethics application status

Summary

Brief summary

This Phase Ib/II, open-label, multicenter, non-randomized study will evaluate the safety,
efficacy, and pharmacokinetics of idasanutlin when it is given in combination with cytarabine
and daunorubicin in induction, in combination with cytarabine in consolidation, and as a
single agent in maintenance for treating participants with acute myeloid leukemia (AML).

Trial website

https://clinicaltrials.gov/ct2/show/NCT03850535

Public notes

Contacts

Principal investigator

Name

Clinical Trials

Address

Hoffmann-La Roche

Country

Phone

Email

Contact person for public queries

Name

Address

Country

Phone

Email

Contact person for scientific queries

Trial Review

For full trial details, please see the original record at https://clinicaltrials.gov/ct2/show/NCT03850535